PMID- 26195265
OWN - NLM
STAT- MEDLINE
DCOM- 20161007
LR  - 20161230
IS  - 1752-8976 (Electronic)
IS  - 1470-3203 (Linking)
VI  - 16
IP  - 4
DP  - 2015 Dec
TI  - Dipeptidyl peptidase-4 inhibitor sitagliptin improves pancreatic beta-cell function 
      in hypertensive diabetic patients treated with angiotensin receptor blockers.
PG  - 1001-9
LID - 10.1177/1470320315587180 [doi]
AB  - INTRODUCTION: Dipeptidyl peptidase (DPP)-4 inhibitors, a novel oral anti-diabetic 
      agents, exert a protective effect on pancreatic beta-cell function in patients with 
      type 2 diabetic mellitus (T2DM). However, their beneficial effect in hypertensive 
      T2DM patients treated with angiotensin receptor blockers (ARBs) has not been 
      investigated. METHODS: In this open-label multicenter randomized study, a total 
      of 55 hypertensive T2DM patients treated with ARBs were randomly assigned to 
      receive the DPP-4 inhibitor sitagliptin or sulfonylurea (SU). RESULTS: After 24 
      weeks of treatment, a significant reduction in fasting blood glucose was only 
      observed in the sitagliptin group, while HbA1c was significantly reduced in both 
      groups. Homeostasis model assessment of insulin resistance was not significantly 
      improved in either group. Indicators of pancreatic beta-cell function, including 
      proinsulin to insulin ratio and homeostasis model assessment of beta-cell function, 
      were significantly improved in the sitagliptin group, but not in the SU group. 
      The beneficial effects of sitagliptin were observed in hypoglycemic drug naive 
      patients, but not in patients who had received SU monotherapy prior to the study. 
      CONCLUSION: Treatment with the DPP-4 inhibitor sitagliptin might exert beneficial 
      effects on pancreatic beta-cell function in ARB-treated T2DM patients and its 
      efficacy might be more pronounced in hypoglycemic drug naive patients.
CI  - (c) The Author(s) 2015.
FAU - Fukui, Kensuke
AU  - Fukui K
AD  - Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, 
      Japan.
FAU - Kawahito, Hiroyuki
AU  - Kawahito H
AD  - Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, 
      Japan.
FAU - Wakana, Noriyuki
AU  - Wakana N
AD  - Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, 
      Japan.
FAU - Kikai, Masakazu
AU  - Kikai M
AD  - Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, 
      Japan.
FAU - Terada, Kensuke
AU  - Terada K
AD  - Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, 
      Japan.
FAU - Yamamoto, Keita
AU  - Yamamoto K
AD  - Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, 
      Japan.
FAU - Irie, Daisuke
AU  - Irie D
AD  - Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, 
      Japan.
FAU - Kato, Taku
AU  - Kato T
AD  - Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, 
      Japan.
FAU - Miyagawa, Sonoko
AU  - Miyagawa S
AD  - Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, 
      Japan.
FAU - Yamada, Hiroyuki
AU  - Yamada H
AD  - Department of Cardiovascular Medicine, Kyoto Prefectural University of Medicine, 
      Japan hiyamada@koto.kpu-m.ac.jp.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20150720
PL  - England
TA  - J Renin Angiotensin Aldosterone Syst
JT  - Journal of the renin-angiotensin-aldosterone system : JRAAS
JID - 100971636
RN  - 0 (Angiotensin Receptor Antagonists)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
RN  - TS63EW8X6F (Sitagliptin Phosphate)
SB  - IM
MH  - Aged
MH  - Angiotensin Receptor Antagonists/pharmacology/*therapeutic use
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/pathology
MH  - Dipeptidyl-Peptidase IV Inhibitors/pharmacology/*therapeutic use
MH  - Female
MH  - Humans
MH  - Hypertension/complications/*drug therapy
MH  - Hypoglycemic Agents/pharmacology/therapeutic use
MH  - Insulin-Secreting Cells/drug effects/*pathology
MH  - Male
MH  - Sitagliptin Phosphate/pharmacology/*therapeutic use
MH  - Sulfonylurea Compounds/therapeutic use
OTO - NOTNLM
OT  - Type 2 diabetes mellitus
OT  - angiotensin receptor blockers
OT  - dipeptidyl peptidase-4 inhibitors
OT  - pancreatic beta-cell function
OT  - proinsulin
EDAT- 2015/07/22 06:00
MHDA- 2016/10/08 06:00
CRDT- 2015/07/22 06:00
PHST- 2015/01/22 00:00 [received]
PHST- 2015/04/13 00:00 [accepted]
PHST- 2015/07/22 06:00 [entrez]
PHST- 2015/07/22 06:00 [pubmed]
PHST- 2016/10/08 06:00 [medline]
AID - 1470320315587180 [pii]
AID - 10.1177/1470320315587180 [doi]
PST - ppublish
SO  - J Renin Angiotensin Aldosterone Syst. 2015 Dec;16(4):1001-9. doi: 
      10.1177/1470320315587180. Epub 2015 Jul 20.